{"transactions":[{"id":688023,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-08-13T20:21:37.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":210000,"price":17.4,"value":3654000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.67 per share, inclusive. The Reporting Person\nundertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the ranges set forth in the footnote."}],"balance_after":35171,"source":{"system":"sec-edgar","filing":"0001628280-26-056754","document":"wk-form4_1786652494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026056754/wk-form4_1786652494.xml","form_type":"4"}},{"id":688022,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-08-13T20:21:37.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":6613,"price":17.7,"value":117050.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.65 to $17.73 per share, inclusive. The Reporting Person\nundertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the ranges set forth in the footnote."}],"balance_after":245171,"source":{"system":"sec-edgar","filing":"0001628280-26-056754","document":"wk-form4_1786652494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026056754/wk-form4_1786652494.xml","form_type":"4"}},{"id":858618,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":35880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":71760,"derivative":{"underlying":"Class A Common Stock","underlying_shares":35880},"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858617,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":305810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":305810},"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858616,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":24258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":72774,"derivative":{"underlying":"Class A Common Stock","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858615,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":38226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":38227,"derivative":{"underlying":"Class A Common Stock","underlying_shares":38226},"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858614,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":22645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":22645},"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858613,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":15580,"price":13.3,"value":207214.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":251784,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858612,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":35880,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":267364,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858611,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":132783,"price":13.31,"value":1767341.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units."}],"balance_after":231484,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858610,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":305810,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.  On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period.  These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":364267,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858609,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":10533,"price":13.31,"value":140194.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":58457,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858608,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":68990,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858607,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":16598,"price":13.31,"value":220919.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":44732,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858606,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":38226,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":61330,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858605,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":10147,"price":13.31,"value":135056.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":23104,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":858604,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-05T21:32:25.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":22645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":33251,"source":{"system":"sec-edgar","filing":"0001628280-26-015241","document":"wk-form4_1772746340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026015241/wk-form4_1772746340.xml","form_type":"4"}},{"id":867533,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2026-03-03T21:27:20.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":65359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period."}],"balance_after":65359,"derivative":{"underlying":"Class A Common Stock","underlying_shares":65359},"source":{"system":"sec-edgar","filing":"0001628280-26-013882","document":"wk-form4_1772573232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026013882/wk-form4_1772573232.xml","form_type":"4"}},{"id":867532,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T21:27:20.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":65359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 2, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 2, 2027."}],"balance_after":65359,"derivative":{"underlying":"Class A Common Stock","underlying_shares":65359},"source":{"system":"sec-edgar","filing":"0001628280-26-013882","document":"wk-form4_1772573232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026013882/wk-form4_1772573232.xml","form_type":"4"}},{"id":1067823,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-08-13T20:39:26.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":22000,"price":9.05,"value":199100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.01 to $9.13 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":10606,"source":{"system":"sec-edgar","filing":"0001723128-25-000049","document":"wk-form4_1755117561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000049/wk-form4_1755117561.xml","form_type":"4"}},{"id":1217481,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-07T21:17:53.000Z","date":"2025-03-06","kind":"sale","planned":false,"acquired":false,"shares":46936,"price":8.73,"value":409751.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.64 to $8.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":32606,"source":{"system":"sec-edgar","filing":"0001628280-25-011306","document":"wk-form4_1741382266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025011306/wk-form4_1741382266.xml","form_type":"4"}},{"id":1217480,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-07T21:17:53.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":43064,"price":8.88,"value":382408.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $9.00 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote."}],"balance_after":79542,"source":{"system":"sec-edgar","filing":"0001628280-25-011306","document":"wk-form4_1741382266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025011306/wk-form4_1741382266.xml","form_type":"4"}},{"id":1222620,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":35879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On March 4, 2024, the Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On March 4, 2024, the Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":107640,"derivative":{"underlying":"Class A Common Stock","underlying_shares":35879},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222619,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":97032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2026."}],"balance_after":97032,"derivative":{"underlying":"Class A Common Stock","underlying_shares":97032},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222618,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":194064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 97,032 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents a performance-based restricted stock unit grant of 97,032 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period."}],"balance_after":194064,"derivative":{"underlying":"Class A Common Stock","underlying_shares":194064},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222617,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":90580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":90580},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222616,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":38226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":76453,"derivative":{"underlying":"Class A Common Stock","underlying_shares":38226},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222615,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":22645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":22645,"derivative":{"underlying":"Class A Common Stock","underlying_shares":22645},"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222614,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":15579,"price":8.84,"value":137718.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents Shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":122606,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222613,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":35879,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."}],"balance_after":138185,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222612,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":31338,"price":8.76,"value":274520.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units."}],"balance_after":102306,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222611,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":90580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted\nperformance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These\nunits were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis.  Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 5."}],"balance_after":133644,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222610,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":10864,"price":8.76,"value":95168.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents Shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":43064,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222609,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":38226,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."}],"balance_after":53928,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222608,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":6943,"price":8.76,"value":60820.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents Shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":15702,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1222607,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-03-06T01:21:34.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":22645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units.  The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations.  See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock."}],"balance_after":22645,"source":{"system":"sec-edgar","filing":"0001628280-25-010719","document":"wk-form4_1741224087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828025010719/wk-form4_1741224087.xml","form_type":"4"}},{"id":1354370,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-22T21:38:33.000Z","date":"2024-11-21","kind":"sale","planned":false,"acquired":false,"shares":13665,"price":8.4,"value":114786.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-049005","document":"wk-form4_1732311507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024049005/wk-form4_1732311507.xml","form_type":"4"}},{"id":1359259,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-19T21:17:06.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":43657,"price":8.61,"value":375886.77,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price included in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $8.50 to $9.00 per share, inclusive.  The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":13665,"source":{"system":"sec-edgar","filing":"0001628280-24-048437","document":"wk-form4_1732051018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024048437/wk-form4_1732051018.xml","form_type":"4"}},{"id":1596645,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":287038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period."}],"balance_after":287038,"derivative":{"underlying":"Class A Common Stock","underlying_shares":287038},"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596644,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":143519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units vest in four equal annual installments beginning on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units vest in four equal annual installments beginning on March 4, 2025."}],"balance_after":143519,"derivative":{"underlying":"Class A Common Stock","underlying_shares":143519},"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596643,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":38226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":114679,"derivative":{"underlying":"Class A Common Stock","underlying_shares":38226},"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596642,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":22645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":45290,"derivative":{"underlying":"Class A Common Stock","underlying_shares":22645},"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596641,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":10864,"price":5.47,"value":59426.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":57322,"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596640,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":38226,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":68186,"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596639,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":7166,"price":5.47,"value":39198.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":29960,"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1596638,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2024-03-05T21:54:16.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":22645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":37126,"source":{"system":"sec-edgar","filing":"0001628280-24-008977","document":"wk-form4_1709675630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024008977/wk-form4_1709675630.xml","form_type":"4"}},{"id":1966079,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2023-03-07T23:00:25.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":305810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period."}],"balance_after":305810,"derivative":{"underlying":"Class A Common Stock","underlying_shares":305810},"source":{"system":"sec-edgar","filing":"0001209191-23-016935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016935/doc4.xml","form_type":"4"}},{"id":1966078,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-07T23:00:25.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":152905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2024."}],"balance_after":152905,"derivative":{"underlying":"Class A Common Stock","underlying_shares":152905},"source":{"system":"sec-edgar","filing":"0001209191-23-016935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016935/doc4.xml","form_type":"4"}},{"id":1966077,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-07T23:00:25.000Z","date":"2023-03-03","kind":"exercise","acquired":false,"shares":22645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date."}],"balance_after":67935,"derivative":{"underlying":"Class A Common Stock","underlying_shares":22645},"source":{"system":"sec-edgar","filing":"0001209191-23-016935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016935/doc4.xml","form_type":"4"}},{"id":1966076,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2023-03-07T23:00:25.000Z","date":"2023-03-03","kind":"tax_withholding","acquired":false,"shares":8164,"price":1.92,"value":15674.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units."}],"balance_after":14481,"source":{"system":"sec-edgar","filing":"0001209191-23-016935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016935/doc4.xml","form_type":"4"}},{"id":1966075,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2023-03-07T23:00:25.000Z","date":"2023-03-03","kind":"exercise","acquired":true,"shares":22645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":22645,"source":{"system":"sec-edgar","filing":"0001209191-23-016935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919123016935/doc4.xml","form_type":"4"}},{"id":2354817,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2022-03-04T02:18:04.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":181160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a performance-based restricted stock unit grant of 90,580 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 90,580 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a performance-based restricted stock unit grant of 90,580 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents a performance-based restricted stock unit grant of 90,580 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents a performance-based restricted stock unit grant of 90,580 target shares.  The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award.  The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number.  The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award.  Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period."}],"balance_after":181160,"derivative":{"underlying":"Class A Common Stock","underlying_shares":181160},"source":{"system":"sec-edgar","filing":"0001209191-22-016049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016049/doc4.xml","form_type":"4"}},{"id":2354816,"issuer":{"id":820,"kind":"organization","name":"Amneal Pharmaceuticals, Inc.","symbol":"AMRX"},"owners":[{"id":23705,"kind":"person","name":"Daly Jason B.","position":1,"cik":"0001906486","reported_name":"Daly Jason B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-04T02:18:04.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":90580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on March 3, 2023."}],"balance_after":90580,"derivative":{"underlying":"Class A Common Stock","underlying_shares":90580},"source":{"system":"sec-edgar","filing":"0001209191-22-016049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723128/000120919122016049/doc4.xml","form_type":"4"}}]}